Author's Response to Letter to the Editor Concerning "Glucagon-Like Peptide Agonists for Weight Management in Antipsychotic-Induced Weight Gain: A Systematic Review and Meta-Analysis" by Anders Fink-Jensen|Christoph U. Correll.
作者信息
Campforts Bea, Bak Maarten, Domen Patrick, van Amelsvoort Therese, Drukker Marjan
机构信息
Department of Psychiatry & Neuropsychology, Maastricht University, Maastricht, The Netherlands.
出版信息
Acta Psychiatr Scand. 2024 Dec 22;151(5):644-5. doi: 10.1111/acps.13784.
Abstract
摘要
相似文献
1
Author's Response to Letter to the Editor Concerning "Glucagon-Like Peptide Agonists for Weight Management in Antipsychotic-Induced Weight Gain: A Systematic Review and Meta-Analysis" by Anders Fink-Jensen|Christoph U. Correll.作者对编辑就安德斯·芬克 - 詹森|克里斯托夫·U·科雷尔所著《胰高血糖素样肽激动剂用于抗精神病药物所致体重增加的体重管理：系统评价和荟萃分析》的来信的回复
Acta Psychiatr Scand. 2024 Dec 22;151(5):644-5. doi: 10.1111/acps.13784.
2
Letter to the Editor Concerning "Glucagon-Like Peptide Agonists for Weight Management in Antipsychotic-Induced Weight Gain: A Systematic Review and Meta-Analysis".致编辑的信：关于“胰高血糖素样肽激动剂用于抗精神病药物所致体重增加的体重管理：一项系统评价和荟萃分析”
Acta Psychiatr Scand. 2025 Apr;151(4):548-549. doi: 10.1111/acps.13772. Epub 2024 Nov 14.
3
The quantity, quality and findings of network meta-analyses evaluating the effectiveness of GLP-1 RAs for weight loss: a scoping review.评估胰高血糖素样肽-1受体激动剂（GLP-1 RAs）减肥效果的网状Meta分析的数量、质量及结果：一项范围综述
Health Technol Assess. 2025 Jun 25:1-73. doi: 10.3310/SKHT8119.
4
Glucagon-like peptide agonists for weight management in antipsychotic-induced weight gain: A systematic review and meta-analysis.用于抗精神病药物所致体重增加的体重管理的胰高血糖素样肽激动剂：一项系统评价和荟萃分析。
Acta Psychiatr Scand. 2024 Dec;150(6):516-529. doi: 10.1111/acps.13734. Epub 2024 Jul 24.
5
Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials.七种胰高血糖素样肽-1 受体激动剂和多激动剂在肥胖或超重患者中的减肥作用：一项更新的随机对照试验的系统评价和网络荟萃分析。
Metabolism. 2024 Dec;161:156038. doi: 10.1016/j.metabol.2024.156038. Epub 2024 Sep 19.
6
Fixed ratio combinations of glucagon like peptide 1 receptor agonists with basal insulin: a systematic review and meta-analysis.胰高血糖素样肽-1受体激动剂与基础胰岛素的固定比例组合：一项系统评价和荟萃分析。
Endocrine. 2017 Jun;56(3):485-494. doi: 10.1007/s12020-017-1293-6. Epub 2017 Apr 12.
7
Glucagon-like peptide-1 receptor agonists in adolescents with overweight or obesity with or without type 2 diabetes multimorbidity-a systematic review and network meta-analysis.胰高血糖素样肽-1受体激动剂用于合并或不合并2型糖尿病的超重或肥胖青少年——一项系统评价和网状Meta分析
Diabetes Obes Metab. 2024 Oct;26(10):4302-4317. doi: 10.1111/dom.15777. Epub 2024 Jul 23.
8
Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.胰高血糖素样肽-1 受体激动剂对体重减轻的影响：随机对照试验的系统评价和荟萃分析。
BMJ. 2012 Jan 10;344:d7771. doi: 10.1136/bmj.d7771.
9
Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis.使用双重 GIP/GLP-1 受体激动剂替西帕肽治疗 2 型糖尿病：系统评价和荟萃分析。
Diabetologia. 2022 Aug;65(8):1251-1261. doi: 10.1007/s00125-022-05715-4. Epub 2022 May 17.
10
SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline.钠-葡萄糖协同转运蛋白 2 抑制剂或胰高血糖素样肽-1 受体激动剂治疗 2 型糖尿病成人患者：临床实践指南。
BMJ. 2021 May 11;373:n1091. doi: 10.1136/bmj.n1091.
本文引用的文献
1
Management of obesity with semaglutide or metformin in patients with antipsychotic-induced weight gain (MOSA): a non-randomised open-label pilot study.在抗精神病药引起体重增加的患者中，用司美格鲁肽或二甲双胍治疗肥胖症（MOSA）：一项非随机开放标签的初步研究。
BMC Psychiatry. 2024 Nov 30;24(1):865. doi: 10.1186/s12888-024-06317-7.
2
Letter to the Editor Concerning "Glucagon-Like Peptide Agonists for Weight Management in Antipsychotic-Induced Weight Gain: A Systematic Review and Meta-Analysis".致编辑的信：关于“胰高血糖素样肽激动剂用于抗精神病药物所致体重增加的体重管理：一项系统评价和荟萃分析”
Acta Psychiatr Scand. 2025 Apr;151(4):548-549. doi: 10.1111/acps.13772. Epub 2024 Nov 14.
3
Glucagon-like peptide agonists for weight management in antipsychotic-induced weight gain: A systematic review and meta-analysis.用于抗精神病药物所致体重增加的体重管理的胰高血糖素样肽激动剂：一项系统评价和荟萃分析。
Acta Psychiatr Scand. 2024 Dec;150(6):516-529. doi: 10.1111/acps.13734. Epub 2024 Jul 24.
4
GLP-1 receptor agonists and weight loss in schizophrenia - past, present, and future.GLP-1 受体激动剂与精神分裂症患者的体重减轻：过去、现在与未来。
Curr Opin Psychiatry. 2024 Sep 1;37(5):363-369. doi: 10.1097/YCO.0000000000000952. Epub 2024 Jun 7.
5
Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin - a case series.司美格鲁肽治疗二甲双胍治疗无效的抗精神病药物所致体重增加患者——病例系列
Ther Adv Psychopharmacol. 2023 Apr 19;13:20451253231165169. doi: 10.1177/20451253231165169. eCollection 2023.
6
Representation and Outcomes of Individuals With Schizophrenia Seen in Everyday Practice Who Are Ineligible for Randomized Clinical Trials.日常实践中不符合随机临床试验条件的精神分裂症患者的特征及结局
JAMA Psychiatry. 2022 Mar 1;79(3):210-218. doi: 10.1001/jamapsychiatry.2021.3990.
Zotero 插件